Molecular pathological classification method of diffuse large B-cell lymphomata, kit and application thereof

A technology of pathological typing and B cells, which is applied in the field of hematology oncology and medicine, can solve the problems of low efficiency and cumbersome operation, and achieve the effects of good repeatability, improved work efficiency and reduced cost
CN101968491AInactive Publication Date: 2011-02-09SHANGHAI BIOCHIP +1
6 Cites 7 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
SHANGHAI BIOCHIP
Publication Date
2011-02-09
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a molecular pathological classification method of diffuse large B-cell lymphomata, which use three quantum dot markers of different wavelengths as fluorescent probes to detect the expression of CD10, Bcl-6 and MUM1 proteins in a biological sample. The invention also discloses a kit for the molecular pathological classification of diffuse large B-cell lymphomata and an application thereof. The molecular pathological classification method of diffuse large B-cell lymphomata obviously improves the working efficiency, and can provide a rational regimen for patients with diffuse large B-cell lymphomata, thereby being beneficial to saving medical expenses.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the fields of hemato-oncology and medicine, in particular to a molecular pathological typing method, kit and application of diffuse large B-cell lymphoma. Background technique

[0002] Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma, accounting for about 40% of newly diagnosed non-Hodgkin's lymphoma each year. The current incidence of non-Hodgkin's lymphoma in my country is about 3-4 / 100,000, and it is increasing at a rate of 2-3% per year, among which diffuse large B-cell lymphoma (DLBCL) is the most common, accounting for about 50% of tumors, therefore, the annual national new cases are about 20,000-30,000.

[0003] DLBCL has significant biological heterogeneity, and patients have significant differences in response to treatment. The conventional CHOP combined chemotherapy regimen (cyclophosphamide, doxorubicin, vincristine and prednisone) can only make about 40% of patients Get long-term reli...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More